A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2013
At a glance
- Drugs Carbidopa/XP-21279 (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors XenoPort
- 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
- 05 Dec 2011 Primary endpoint 'Off-time' has not been met, according to a XenoPort media release.
- 04 Aug 2011 Top-line results are expected by the end of 2011, according to a XenoPort media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History